Reolysin (pelareorep) / Oncolytics, Andrus Reo, Adlai Nortye 
Welcome,         Profile    Billing    Logout  

8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reolysin (pelareorep) / Oncolytics, Andrus Reo
BRACELET-1, NCT04215146: A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - Study

Active, not recruiting
2
48
US
Paclitaxel, Pelareorep, Avelumab
Oncolytics Biotech, PrECOG, LLC.
Breast Cancer Metastatic
08/22
07/24
NCI-2020-02940, NCT04445844: INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Checkmark Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Dec 2021 - Dec 2021: Presentation of data in combination with pelareorep for metastatic TNBC from IRENE study at SABCS 2021
Recruiting
2
25
US
Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Retifanlimab, INCMGA 0012, INCMGA-0012, INCMGA00012, INCMGA0012, MGA 012, MGA-012, MGA012
Mridula George, MD, Incyte Corporation, Oncolytics Biotech, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
06/24
09/24
AMBUSH, NCT05514990: Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, Trial

Recruiting
1/2
42
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of Southern California, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
10/25
10/26
REO 019, NCT02514382: Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
1b
14
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus, Reolysin
University of Southern California, National Cancer Institute (NCI), Oncolytics Biotech
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
04/22
04/22
NCT02444546: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Completed
1
6
US
Laboratory Biomarker Analysis, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Wild-type Reovirus, Reolysin
Mayo Clinic, National Cancer Institute (NCI)
Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
07/18
11/22
NCT02101944: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Completed
1
12
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus
National Cancer Institute (NCI)
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
05/21
05/24
NCT05519059: Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Completed
1
15
RoW
Pelareorep, Paclitaxel
Adlai Nortye Biopharma Co., Ltd.
Advanced or Metastatic Breast Cancer
09/22
05/23
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Checkmark Updated results
Dec 2018 - Dec 2018: Updated results
Completed
1
23
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus
Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Plasma Cell Myeloma
10/22
10/22

Download Options